搜尋結果
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.{br}{br}TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.{br}{br}TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites.
台微體子公司公佈瑞德西韋先驅活性物新劑型之策略 於科學大會發表ISPM21及ISPM19治療新冠肺炎之優勢
2020年8月14日 · TLC19 運用既有台微體獨家微脂體包覆技術平台,以口服 HCQ 近百分之一的劑量改良成吸入劑型,直接傳遞至上呼吸道及肺部目標組織。
TLC599 乃台微體獨家「 BioSeizer ® 」長效緩釋配方之地塞米松磷酸鈉藥物,一針即可快速且持續緩解關節炎帶來之疼痛。 TLC599的脂質配方在臨床前研究中,即使重複給藥,也未觀察到蛋白聚醣損失。
一、發言人及代理發言人姓名、職稱、聯絡電話及電子郵件信箱 發言人 代 理 發 言 人 姓名 曾雲龍 施雪芳 周步朗 職稱 副 ...
Moved Permanently. The document has moved here.